Fosamax and Osteonecrosis of the Jaw: Clinical Evidence Review
Latest update (2026-05)
FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]
From General Health Education to Targeted Risk Communication
The legacy of general health and science communication has long provided the public with foundational knowledge about disease prevention, treatment options, and the importance of informed medical decision-making. Within this broad context, discussions of bone health have traditionally centered on osteoporosis management, fracture risk reduction, and the role of bisphosphonate therapies in maintaining skeletal integrity. These conversations have served as a critical bridge between complex biomedical research and everyday health literacy, empowering individuals to engage with their healthcare providers about therapeutic benefits and potential adverse effects. As this informational heritage evolves, a more focused examination has emerged regarding specific exposure scenarios and their downstream health implications. The transition from general health education to occupational and clinical exposure concern is marked by a growing recognition that certain pharmaceutical agents, when used over extended periods, may be associated with unexpected tissue-level outcomes. This pivot does not require invoking specific disease mechanisms; rather, it reflects a natural progression in risk communication—moving from broad awareness to targeted scrutiny of exposure circumstances. In the context of bisphosphonate therapy, this shift directs attention toward the relationship between drug exposure duration, patient-specific factors, and the potential for rare but serious oral complications.
Clinical Evidence Linking Fosamax to Osteonecrosis of the Jaw
Fosamax (alendronate sodium) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its clinical utility in reducing fracture risk is well established, but its use has been associated with a serious adverse effect: osteonecrosis of the jaw (ONJ). Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region. Clinical presentation typically involves areas of necrotic bone that persist for weeks to months, often accompanied by pain, swelling, infection, or drainage. Diagnosis is based on clinical examination and imaging, with a focus on ruling out other causes such as malignancy or radiation-induced osteonecrosis. The condition can occur spontaneously but is generally associated with tooth extraction, local infection, or delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, or ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The mechanistic pathways linking Fosamax to ONJ are not fully elucidated, but current evidence suggests that bisphosphonates, including alendronate, alter bone remodeling by inhibiting osteoclast activity. This suppression of bone turnover may impair the jawbone's ability to repair microdamage and respond to local stressors such as dental procedures or infection. Multiscale characterization of jawbone tissue has provided comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). The jawbone's high rate of remodeling and its unique anatomical and functional demands may make it particularly vulnerable to the effects of bisphosphonate therapy.
For affected patients, causation-related considerations involve assessing the temporal relationship between Fosamax exposure and the development of ONJ, as well as the presence of other risk factors. The timeline between exposure and documented harm can range from days to months, and the condition may be exacerbated by dental procedures or local infection. Patients who develop ONJ while on Fosamax should be evaluated for alternative causes, but the drug's known association with ONJ supports a potential causal link. Management includes discontinuation of the bisphosphonate, symptomatic treatment, and dental care to address infection or necrotic bone. In summary, Fosamax is an effective bisphosphonate for osteoporosis and other bone conditions, but its use carries a risk of ONJ, particularly in patients with additional risk factors such as dental procedures or cancer therapies. The prescribing information provides warnings and risk mitigation strategies, but the variable onset and potential for recurrence highlight the need for careful patient monitoring and shared decision-making regarding treatment duration and dental care.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is Fosamax and how is it used?
Fosamax (alendronate sodium) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).
What is osteonecrosis of the jaw (ONJ) and how is it related to Fosamax?
Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region, often associated with pain, swelling, infection, or drainage. Fosamax use has been associated with ONJ, particularly in patients with additional risk factors such as dental procedures or cancer therapies (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).
What are the risk factors for developing ONJ while taking Fosamax?
Known risk factors include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, or ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).
How long does it take for ONJ to develop after starting Fosamax?
What should I do if I develop symptoms of ONJ while taking Fosamax?
If you develop symptoms such as jaw pain, swelling, or exposed bone, consult your healthcare provider immediately. Management may include discontinuation of the bisphosphonate, symptomatic treatment, and dental care to address infection or necrotic bone.
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
Free and confidential. No obligation — an initial records screening only.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.